000057304 001__ 57304
000057304 005__ 20161225215125.0
000057304 0247_ $$2WOS$$aWOS:000239765700008
000057304 037__ $$aPreJuSER-57304
000057304 041__ $$aeng
000057304 082__ $$a610
000057304 084__ $$2WoS$$aRadiology, Nuclear Medicine & Medical Imaging
000057304 1001_ $$0P:(DE-HGF)0$$aRisse, J. H.$$b0
000057304 245__ $$aTherapy of hepatocellular carcinoma with iodine-131-lipiodol: results in a large German cohort
000057304 260__ $$aStuttgart$$bSchattauer$$c2006
000057304 300__ $$a185 - 192
000057304 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000057304 3367_ $$2DataCite$$aOutput Types/Journal article
000057304 3367_ $$00$$2EndNote$$aJournal Article
000057304 3367_ $$2BibTeX$$aARTICLE
000057304 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000057304 3367_ $$2DRIVER$$aarticle
000057304 440_0 $$04657$$aNuklearmedizin$$v45$$x0029-5566
000057304 500__ $$aRecord converted from VDB: 12.11.2012
000057304 520__ $$aAim: To evaluate the efficacy and tolerance of iodine-I-131-lipiodol (I-131-lipiodol) for hepatocellular carcinoma (HCC) in German long term patients and comparison with medically treated controls. Patients, Methods: 38 courses of intro-arterial I-131-lipiodol therapy with a total activity up to 6.7 GBq were performed in 18 patients with HCC (6 with portal vein thrombosis). Liver and tumour volume and lipiodol deposition were measured by computed tomography and I-131 activity by scintigraphy. Therapeutic efficacy was determined by tumour volume change and matched-pairs analysis in comparison to medically (i.e. tamoxifen or medical support) treated patients. Results: Tumour volume decreased in 20/32 index nodules (63%) after the first course. Repeated therapy frequently resulted in further tumour reduction. Overall response to treatment was partial in 11 nodules, minor response in 4 nodules, and disease was stable in 12 and progressive in 5. Significant response was associated with pretherapeutic nodule volume up to 150 ml (diameter of 6.6 cm). Survival rate after 3, 6, 9, 12, 24 and 36 months was 78, 61, 50, 39, 17, and 6%. Matched-pairs analysis of survival revealed I-131-lipiodol to be superior to medical treatment. The most important side effect was a pancreatitis-like syndrome whereas overall tolerance was good. Conclusion: The long term results confirm that HCC therapy with I-131-lipiodol is effective and probably superior to medical treatment. Tumour nodules of up to 6 cm diameter are well suited for this therapy even in the presence of portal vein thrombosis.
000057304 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000057304 588__ $$aDataset connected to Web of Science
000057304 650_7 $$2WoSType$$aJ
000057304 65320 $$2Author$$ahepatocellular carcinoma
000057304 65320 $$2Author$$acancer therapy
000057304 65320 $$2Author$$aiodine-131-lipiodol
000057304 65320 $$2Author$$aportal vein thrombosis
000057304 65320 $$2Author$$along term analysis
000057304 7001_ $$0P:(DE-HGF)0$$aRabe, C.$$b1
000057304 7001_ $$0P:(DE-Juel1)VDB6977$$aPauleit, D.$$b2$$uFZJ
000057304 7001_ $$0P:(DE-HGF)0$$aReichmann, K.$$b3
000057304 7001_ $$0P:(DE-HGF)0$$aMenzel, C.$$b4
000057304 7001_ $$0P:(DE-HGF)0$$aGrünwald, F.$$b5
000057304 7001_ $$0P:(DE-HGF)0$$aStrunk, H.$$b6
000057304 7001_ $$0P:(DE-HGF)0$$aBiersack, H.-J.$$b7
000057304 7001_ $$0P:(DE-HGF)0$$aPalmedo, H.$$b8
000057304 773__ $$0PERI:(DE-600)2030804-8$$gVol. 45, p. 185 - 192$$p185 - 192$$q45<185 - 192$$tNuklearmedizin$$v45$$x0029-5566$$y2006
000057304 909CO $$ooai:juser.fz-juelich.de:57304$$pVDB
000057304 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000057304 9141_ $$aNachtrag$$y2006
000057304 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000057304 9201_ $$0I:(DE-Juel1)VDB54$$d31.12.2006$$gIME$$kIME$$lInstitut für Medizin$$x1
000057304 970__ $$aVDB:(DE-Juel1)90124
000057304 980__ $$aVDB
000057304 980__ $$aConvertedRecord
000057304 980__ $$ajournal
000057304 980__ $$aI:(DE-Juel1)INB-3-20090406
000057304 980__ $$aUNRESTRICTED
000057304 981__ $$aI:(DE-Juel1)INB-3-20090406